Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 2/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.52 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.52 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | CXCR6 | O00574 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | DRD3 | P35462 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3871013 | 1.00 | KCNH2 (0.56) | KCNH2MEN1KMT2ANPSR1OPRK1 | |
| SCHEMBL3873441 | 0.90 | NPC1 (0.53) | KCNH2MEN1KMT2AOPRK1ALDH1A1 | |
| SCHEMBL3873444 | 0.90 | NPC1 (0.53) | KCNH2MEN1KMT2AOPRK1ALDH1A1 | |
| SCHEMBL3869677 | 0.88 | ALDH1A1 (0.57) | OPRK1MAPTMAPK1ALDH1A1CXCR6 | |
| SCHEMBL3869675 | 0.88 | ALDH1A1 (0.57) | OPRK1MAPTMAPK1ALDH1A1CXCR6 | |
| SCHEMBL4671746 | 0.88 | RAB9A (0.51) | KCNH2MEN1KMT2ANPSR1OPRK1 | |
| SCHEMBL4671748 | 0.88 | RAB9A (0.51) | KCNH2MEN1KMT2ANPSR1OPRK1 | |
| SCHEMBL4668374 | 0.86 | NPC1 (0.47) | KCNH2MEN1KMT2ANPSR1OPRK1 | |
| SCHEMBL4668370 | 0.86 | NPC1 (0.47) | KCNH2MEN1KMT2ANPSR1OPRK1 | |
| SCHEMBL3870205 | 0.85 | MAPT (0.48) | MEN1KMT2ANPSR1OPRK1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1891064-B1 | N-AMIDE DERIVATIVES OF 8-AZABICYCLO[3.2.1]OCT-3-YL AS CCR1 ANTAGONISTS | ALMIRALL SA (ES) | 2009-09-02 | — | — | EP | claimed |
| US-20090130090-A1 | N-amide Derivatives of 8-Azabicyclo[3.2.1]OCT-3-YL AS CCR1 Antagonists | LABORATORIOS ALMIRALL, S.A. (ES) | 2009-05-21 | — | — | US | claimed |
| EP-1891064-B1 | N-AMIDE DERIVATIVES OF 8-AZABICYCLO[3.2.1]OCT-3-YL AS CCR1 ANTAGONISTS | ALMIRALL SA (ES) | 2009-09-02 | — | — | EP | disclosed |
| US-20090130090-A1 | N-amide Derivatives of 8-Azabicyclo[3.2.1]OCT-3-YL AS CCR1 Antagonists | LABORATORIOS ALMIRALL, S.A. (ES) | 2009-05-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090130090-A1 | N-amide Derivatives of 8-Azabicyclo[3.2.1]OCT-3-YL AS CCR1 Antagonists | CCR1, CCR3, CCR8 | KCNH2 3671/4885MEN1 4445/4885KMT2A 2987/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.